Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

87.68 -0.24 (-0.27%)
Official Closing Price Updated: 7:00 PM EDT, May 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,855,468
Open 87.85
Bid (Size) 87.50 (1)
Ask (Size) 92.19 (1)
Prev. Close 87.92
Today's Range 87.54 - 88.31
52wk Range 79.09 - 95.17
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Analyzing Novartis's Short Interest
Novartis's (NYSE:NVS) short percent of float has risen 3.57% since its last report. The company recently reported that it has 6.56 million shares sold short, which is 0.29% of all... 
Via Benzinga
Pain Management Drugs Market Increased Research Activities Boost Demand Opportunities
Pain Management Drugs Market Increased Research Activities Boost Demand Opportunities The global pain management drugs market was valued at $71,431.85 million in 2019, and is projected to reach... 
Via iCrowdNewswire

Performance

YTD
-0.22%
-0.22%
1 Month
-4.96%
-4.96%
3 Month
-0.30%
-0.30%
6 Month
+7.06%
+7.06%
1 Year
-1.15%
-1.15%

More News

Read More
Current Report: Novartis (NVS)
Via Talk Markets
Asia-Pacific Anti-Inflammatory Therapeutics Market Qualitative Insights on Application & Outlook by Share, Future Growth
Via iCrowdNewswire
Topics Intellectual Property
Exposures Intellectual Property
5 Value Stocks In The Healthcare Sector
Via Benzinga
New Data Shows Novartis' Kisqali Extends Survival In Postmenopausal Breast Cancer Setting
Via Benzinga
Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial
Via Benzinga
Novartis: Q1 Earnings Insights
Via Benzinga
3 Undervalued Stocks to Buy Before You Sell in May and Go Away
Via InvestorPlace
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
Via Investor's Business Daily
Surgical Equipment Market Top Companies, Business Growth & Investment Opportunities, Share
Via iCrowdNewswire
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022
Via Benzinga
Here's The Surprising Source Of Novartis' First-Quarter Sales Growth
Via Investor's Business Daily
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Via Benzinga
Setareh Williams Joins Cobbs Creek Healthcare as Managing Partner/Head of Real-World Evidence and Scientific Communications
Via Newswire.com
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
Earnings Scheduled For April 26, 2022
Via Benzinga
Rancho Biosciences Launches the Single Cell Data Science Consortium With Four Charter Members
Via Newswire.com
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Via Benzinga
Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data
Via Benzinga
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Via Benzinga
Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook
Via Benzinga
Novartis Earnings Preview
Via Benzinga
EMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer Setting
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.